1. Home
  2. NAN vs RIGL Comparison

NAN vs RIGL Comparison

Compare NAN & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAN
  • RIGL
  • Stock Information
  • Founded
  • NAN 1999
  • RIGL 1996
  • Country
  • NAN United States
  • RIGL United States
  • Employees
  • NAN N/A
  • RIGL N/A
  • Industry
  • NAN Investment Managers
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • NAN Finance
  • RIGL Health Care
  • Exchange
  • NAN Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • NAN 342.0M
  • RIGL 335.5M
  • IPO Year
  • NAN N/A
  • RIGL 2000
  • Fundamental
  • Price
  • NAN $10.97
  • RIGL $38.85
  • Analyst Decision
  • NAN
  • RIGL Buy
  • Analyst Count
  • NAN 0
  • RIGL 5
  • Target Price
  • NAN N/A
  • RIGL $38.20
  • AVG Volume (30 Days)
  • NAN 74.6K
  • RIGL 995.6K
  • Earning Date
  • NAN 01-01-0001
  • RIGL 08-05-2025
  • Dividend Yield
  • NAN 4.37%
  • RIGL N/A
  • EPS Growth
  • NAN N/A
  • RIGL N/A
  • EPS
  • NAN N/A
  • RIGL 5.43
  • Revenue
  • NAN N/A
  • RIGL $267,921,000.00
  • Revenue This Year
  • NAN N/A
  • RIGL $59.93
  • Revenue Next Year
  • NAN N/A
  • RIGL N/A
  • P/E Ratio
  • NAN N/A
  • RIGL $7.15
  • Revenue Growth
  • NAN N/A
  • RIGL 105.62
  • 52 Week Low
  • NAN $9.11
  • RIGL $12.66
  • 52 Week High
  • NAN $11.34
  • RIGL $43.72
  • Technical
  • Relative Strength Index (RSI)
  • NAN 37.01
  • RIGL 68.57
  • Support Level
  • NAN $10.89
  • RIGL $39.00
  • Resistance Level
  • NAN $10.94
  • RIGL $42.08
  • Average True Range (ATR)
  • NAN 0.06
  • RIGL 2.32
  • MACD
  • NAN -0.00
  • RIGL -0.37
  • Stochastic Oscillator
  • NAN 33.33
  • RIGL 53.26

About NAN Nuveen New York Quality Municipal Income Fund

Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal, New York State and New York City income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: